These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 39138561)

  • 1. Apolipoprotein E knockout, but not cholesteryl ester transfer protein (CETP)-associated high-density lipoprotein cholesterol (HDL-C) lowering, exacerbates muscle wasting in dysferlin-null mice.
    Sun Z; White Z; Theret M; Bernatchez P
    Lipids Health Dis; 2024 Aug; 23(1):247. PubMed ID: 39138561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limb-girdle muscular dystrophy type 2B causes HDL-C abnormalities in patients and statin-resistant muscle wasting in dysferlin-deficient mice.
    White Z; Sun Z; Sauge E; Cox D; Donen G; Pechkovsky D; Straub V; Francis GA; Bernatchez P
    Skelet Muscle; 2022 Nov; 12(1):25. PubMed ID: 36447272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased nonHDL cholesterol levels cause muscle wasting and ambulatory dysfunction in the mouse model of LGMD2B.
    Sellers SL; Milad N; White Z; Pascoe C; Chan R; Payne GW; Seow C; Rossi F; Seidman MA; Bernatchez P
    J Lipid Res; 2018 Feb; 59(2):261-272. PubMed ID: 29175948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotype interaction of apobec-1 and CETP, LDLR, and apoE gene expression in mice: role of apoB mRNA editing in lipoprotein phenotype expression.
    Nakamuta M; Taniguchi S; Ishida BY; Kobayashi K; Chan L
    Arterioscler Thromb Vasc Biol; 1998 May; 18(5):747-55. PubMed ID: 9598833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholesterol absorption blocker ezetimibe prevents muscle wasting in severe dysferlin-deficient and mdx mice.
    White Z; Theret M; Milad N; Tung LW; Chen WW; Sirois MG; Rossi F; Bernatchez P
    J Cachexia Sarcopenia Muscle; 2022 Feb; 13(1):544-560. PubMed ID: 34927367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deficiency of Cholesteryl Ester Transfer Protein Protects Against Atherosclerosis in Rabbits.
    Zhang J; Niimi M; Yang D; Liang J; Xu J; Kimura T; Mathew AV; Guo Y; Fan Y; Zhu T; Song J; Ackermann R; Koike Y; Schwendeman A; Lai L; Pennathur S; Garcia-Barrio M; Fan J; Chen YE
    Arterioscler Thromb Vasc Biol; 2017 Jun; 37(6):1068-1075. PubMed ID: 28428219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Common variation in cholesteryl ester transfer protein: relationship of first major adverse cardiovascular events with the apolipoprotein B/apolipoprotein A-I ratio and the total cholesterol/high-density lipoprotein cholesterol ratio.
    Kappelle PJ; Gansevoort RT; Hillege HJ; Wolffenbuttel BH; Dullaart RP;
    J Clin Lipidol; 2013; 7(1):56-64. PubMed ID: 23351584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of CETP (Cholesteryl Ester Transfer Protein) in the Shift of Sphingosine-1-Phosphate Among Lipoproteins and in the Modulation of its Functions.
    Kurano M; Hara M; Ikeda H; Tsukamoto K; Yatomi Y
    Arterioscler Thromb Vasc Biol; 2017 Mar; 37(3):506-514. PubMed ID: 28126827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A promotive effect for halofuginone on membrane repair and synaptotagmin-7 levels in muscle cells of dysferlin-null mice.
    Barzilai-Tutsch H; Dewulf M; Lamaze C; Butler Browne G; Pines M; Halevy O
    Hum Mol Genet; 2018 Aug; 27(16):2817-2829. PubMed ID: 29771357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thermoneutral Housing and a Western Diet Combination Exacerbates Dysferlin-Deficient Muscular Dystrophy.
    Donen GS; White Z; Sauge E; Ritso M; Theret M; Boyd J; Devlin AM; Rossi FMV; Bernatchez P
    Muscle Nerve; 2022 Oct; 66(4):513-522. PubMed ID: 35859452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of Cholesteryl Ester Transfer Protein Preserves High-Density Lipoprotein Cholesterol and Improves Survival in Sepsis.
    Trinder M; Wang Y; Madsen CM; Ponomarev T; Bohunek L; Daisely BA; Julia Kong H; Blauw LL; Nordestgaard BG; Tybjærg-Hansen A; Wurfel MM; Russell JA; Walley KR; Rensen PCN; Boyd JH; Brunham LR
    Circulation; 2021 Mar; 143(9):921-934. PubMed ID: 33228395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?
    Nurmohamed NS; Ditmarsch M; Kastelein JJP
    Cardiovasc Res; 2022 Nov; 118(14):2919-2931. PubMed ID: 34849601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Restoration of high-density lipoprotein levels by cholesteryl ester transfer protein expression in scavenger receptor class B type I (SR-BI) knockout mice does not normalize pathologies associated with SR-BI deficiency.
    Hildebrand RB; Lammers B; Meurs I; Korporaal SJ; De Haan W; Zhao Y; Kruijt JK; Praticò D; Schimmel AW; Holleboom AG; Hoekstra M; Kuivenhoven JA; Van Berkel TJ; Rensen PC; Van Eck M
    Arterioscler Thromb Vasc Biol; 2010 Jul; 30(7):1439-45. PubMed ID: 20431066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased plasma lipid levels exacerbate muscle pathology in the mdx mouse model of Duchenne muscular dystrophy.
    Milad N; White Z; Tehrani AY; Sellers S; Rossi FMV; Bernatchez P
    Skelet Muscle; 2017 Sep; 7(1):19. PubMed ID: 28899419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Compound heterozygous DYSF variants causing limb-girdle muscular dystrophy type 2B in a Chinese family.
    Li L; Jing Z; Cheng L; Liu W; Wang H; Xu Y; Zheng X; Yu X; Liu S
    J Gene Med; 2020 Nov; 22(11):e3272. PubMed ID: 32889728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-expression of cholesteryl ester transfer protein and defective apolipoprotein E in transgenic mice alters plasma cholesterol distribution. Implications for the pathogenesis of type III hyperlipoproteinemia.
    Fazio S; Marotti KR; Lee YL; Castle CK; Melchior GW; Rall SC
    J Biol Chem; 1994 Dec; 269(51):32368-72. PubMed ID: 7798236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk.
    Ference BA; Kastelein JJP; Ginsberg HN; Chapman MJ; Nicholls SJ; Ray KK; Packard CJ; Laufs U; Brook RD; Oliver-Williams C; Butterworth AS; Danesh J; Smith GD; Catapano AL; Sabatine MS
    JAMA; 2017 Sep; 318(10):947-956. PubMed ID: 28846118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increase in plasma cholesteryl ester transfer protein during probucol treatment. Relation to changes in high density lipoprotein composition.
    McPherson R; Hogue M; Milne RW; Tall AR; Marcel YL
    Arterioscler Thromb; 1991; 11(3):476-81. PubMed ID: 1903061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression.
    van der Hoogt CC; de Haan W; Westerterp M; Hoekstra M; Dallinga-Thie GM; Romijn JA; Princen HM; Jukema JW; Havekes LM; Rensen PC
    J Lipid Res; 2007 Aug; 48(8):1763-71. PubMed ID: 17525476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in high-density lipoprotein-cholesterol subfractions with exercise training may be dependent on cholesteryl ester transfer protein (CETP) genotype.
    Wilund KR; Ferrell RE; Phares DA; Goldberg AP; Hagberg JM
    Metabolism; 2002 Jun; 51(6):774-8. PubMed ID: 12037734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.